会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • METHODS FOR INDUCING T CELL NON-RESPONSIVENESS TO A TISSUE OR ORGAN GRAFT
    • 诱导T细胞对组织或组织细胞无反应的方法
    • WO0100679A2
    • 2001-01-04
    • PCT/US0017730
    • 2000-06-27
    • UNIV MASSACHUSETTSROSSINI ALDO AIWAKOSHI NEALMORDES JOHN PGREINER DALE L
    • ROSSINI ALDO AIWAKOSHI NEALMORDES JOHN PGREINER DALE L
    • A61K38/11C07K16/28C07K16/00
    • C07K16/2875A61K38/00A61K2039/505C07K16/2815
    • Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipient are disclosed. The methods involve administering to a subject antagonists of the receptor which inhibit interaction of the ligand with the receptor, and CD8 T cell depleting agents. In a preferred embodiment, the molecules on the surface of the T cell which mediate contact-dependent helper effector function are CD154. Preferred CD154 antagonists and CD8 T cell depleting agents are anti-CD154 and CD8 antibodies. The CD154 antagonists and CD8 T cell depleting agents are typically administered to a transplant recipient following transplantation of the tissue or organ. The methods of the invention can be used to induce T cell tolerance to transplants such as pancreas, pituitary, liver, kidney, heart, lung, skin, muscle, brain tissue, nerve tissue, stomach, intestines, Adenosine Deaminase-expressing cells, and leptin-expressing cells. A method for treating a skin disorder comprising administering to a subject allogeneic or xenogeneic tissues, organs, or cells expressing donor antigens, CD154 antagonists and CD8 T cell depleting agents and allogeneic skin graft cells is also disclosed.
    • 公开了在移植受体中诱导T细胞对组织或器官移植物的耐受性的方法。 所述方法包括向受试者施用抑制配体与受体相互作用的受体拮抗剂和CD8 + T细胞消耗剂。 在优选的实施方案中,介导接触依赖性辅助效应子功能的T细胞表面上的分子是CD154。 优选的CD154拮抗剂和CD8 + T细胞消耗剂是抗CD154和CD8抗体。 CD154拮抗剂和CD8 + T细胞消耗剂通常在移植组织或器官后给予移植受体。 本发明的方法可用于诱导移植物如胰腺,垂体,肝,肾,心脏,肺,皮肤,肌肉,脑组织,神经组织,胃,肠,腺嘌呤脱氨酶表达细胞的T细胞耐受性和 瘦素表达细胞。 还公开了一种治疗皮肤病症的方法,包括给予受试者同种异体或异种组织,器官或表达供体抗原的细胞,CD154拮抗剂和CD8 + T细胞消耗剂和同种异体皮肤移植细胞。